Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.
Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Wagenlehner FM, et al. Among authors: newell p. Clin Infect Dis. 2016 Sep 15;63(6):754-762. doi: 10.1093/cid/ciw378. Epub 2016 Jun 16. Clin Infect Dis. 2016. PMID: 27313268 Free PMC article. Clinical Trial.
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Mazuski JE, et al. Among authors: newell p. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. Clin Infect Dis. 2016. PMID: 26962078 Free PMC article. Clinical Trial.
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB. Carmeli Y, et al. Among authors: newell p. Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20. Lancet Infect Dis. 2016. PMID: 27107460 Free article. Clinical Trial.
Ceftazidime-avibactam in ceftazidime-resistant infections.
Carmeli Y, Armstrong J, Newell P, Stone G, Wardman A. Carmeli Y, et al. Among authors: newell p. Lancet Infect Dis. 2016 Sep;16(9):997-998. doi: 10.1016/S1473-3099(16)30265-1. Lancet Infect Dis. 2016. PMID: 27684334 No abstract available.
In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.
Stone GG, Bradford PA, Newell P, Wardman A. Stone GG, et al. Among authors: newell p. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e01820-16. doi: 10.1128/AAC.01820-16. Print 2017 Feb. Antimicrob Agents Chemother. 2017. PMID: 27872067 Free PMC article. Clinical Trial.
Reply to Johnson.
Wagenlehner FM, Newell P, Yates K, Gasink LB. Wagenlehner FM, et al. Among authors: newell p. Clin Infect Dis. 2017 Feb 1;64(3):391. doi: 10.1093/cid/ciw713. Epub 2016 Oct 24. Clin Infect Dis. 2017. PMID: 27941118 No abstract available.
262 results